Aprio Wealth Management LLC Buys 1,112 Shares of Eli Lilly and Company $LLY

Key Points

• Aprio Wealth Management increased its Eli Lilly stake by 41.9%, buying 1,112 shares to hold 3,767 shares valued at roughly $4.05 million.
• Eli Lilly reported strong Q1 results—$19.8 billion in revenue (≈+55% YoY) and $8.55 EPS, topping estimates and prompting raised full‑year guidance, driven largely by GLP‑1 products like Mounjaro, Zepbound and the new oral pill Foundayo.
• Regulatory and pricing dynamics present mixed implications: an FDA proposal to limit compounding of tirzepatide/semaglutide could protect branded sales, but lower realized prices and competition/generic approvals abroad remain notable risks.

Aprio Wealth Management LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 41.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,767 shares of the company's stock after buying an additional 1,112 shares during the quarter. Aprio Wealth Management LLC's holdings in Eli Lilly and Company were worth $4,048,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of LLY. Vanguard Group Inc. grew its position in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. State Street Corp boosted its stake in Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company's stock worth $26,496,364,000 after buying an additional 219,590 shares during the period. Capital Research Global Investors raised its stake in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Eli Lilly and Company by 4.1% in the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company's stock worth $11,112,164,000 after acquiring an additional 574,229 shares during the last quarter. Finally, Capital International Investors boosted its stake in shares of Eli Lilly and Company by 6.1% during the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company's stock worth $7,628,447,000 after purchasing an additional 579,381 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Earnings beat and guidance raise — Lilly reported Q1 revenue of $19.8B (up ~56% YoY) and non‑GAAP EPS that topped estimates; management raised full‑year 2026 revenue and EPS guidance. Lilly Q1 press release
• Positive Sentiment: GLP-1 sales are the growth engine — Mounjaro and Zepbound volumes drove huge top‑line growth and analysts/Jim Cramer highlighted the large addressable weight‑loss market as a multi‑year tailwind. GLP-1 Sales Continue to Lift Eli Lilly
• Positive Sentiment: Regulatory move could limit compounded competitors — the FDA proposed excluding active ingredients in tirzepatide/semaglutide from the 503B bulks list, which would curb large‑scale compounding of cheaper alternatives and support branded sales. FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Foundayo pill early uptake — management said more than 20,000 people have started the newly launched oral GLP‑1 pill, supporting upside potential for incremental sales beyond injections. More than 20,000 people are taking Eli Lilly's weight loss pill
• Neutral Sentiment: Pipeline and tech partnerships — Lilly signed a multi‑year ~$2.25B AI/genetics deal to advance recombinase-based gene editing, which is strategic for long‑term growth but not immediately revenue‑generating. Eli Lilly Signs Up To $2.25 Billion AI Gene Editing Deal
• Neutral Sentiment: Full earnings detail available — the Q1 earnings call transcript and slides give color on volume vs. price, channel mix and Foundayo expectations for investors who want to dig into the drivers. Eli Lilly Q1 2026 Earnings Call Transcript
• Negative Sentiment: Pricing pressure and lower realized prices — management noted strong volume but lower realized prices for GLP‑1s partially offset revenue growth; sustained price erosion would limit margin upside. FT: Lilly profits more than double as weight-loss drug sales soar
• Negative Sentiment: Competition and generics risk — approvals of generic GLP‑1s abroad and mixed early social‑data on Foundayo vs. peers create execution and share‑loss risk that investors should monitor. LLY falls as Canada approves generic weight-loss drugs

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a report on Friday, March 6th. Morgan Stanley raised their price objective on Eli Lilly and Company from $1,313.00 to $1,327.00 and gave the stock an "overweight" rating in a report on Friday, April 10th. Truist Financial reiterated a "buy" rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Wells Fargo & Company increased their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Finally, HSBC lowered Eli Lilly and Company from a "hold" rating to a "reduce" rating and cut their price target for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $1,216.52.

Eli Lilly and Company Trading Up 10.1%

Eli Lilly and Company stock opened at $937.04 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a market capitalization of $885.33 billion, a price-to-earnings ratio of 40.83, a price-to-earnings-growth ratio of 1.00 and a beta of 0.51. The stock has a 50-day moving average price of $947.05 and a 200 day moving average price of $984.98.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm's revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 33.79 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.